Glaucoma is a leading cause of blindness in Ontario, and is currently treated using eye drops through a complicated medication schedule (2-3 times daily) that is difficult to follow, particularly by the elderly population. A major part of Frank Gu’s Lab research focuses on developing long-lasting eye drops with tunable release profiles that could significantly reduce dosing requirements. This research could lead to a novel glaucoma medication that could lower the burden on Canadian healthcare cost by reducing the number of preventable cases of blindness due to noncompliance, and bring social benefits and improve the health and quality of life of Canadians.